1. Hopkins, RJ, Girardi, LS, Turney, EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996; 110: 1244–1252.
Google Scholar | Crossref | Medline | ISI2. Hopkins, RJ . Current FDA-approved treatments for Helicobacter pylori and the FDA approval process. Gastroenterology 1997; 113(Suppl. 6): S126–S130.
Google Scholar | Crossref | Medline3. Graham, DY, Canaan, Y, Maher, J, et al. Rifabutin-based triple therapy (RHB-105) for Helicobacter pylori eradication: a double-blind, randomized, controlled trial. Ann Intern Med 2020; 172: 795–802.
Google Scholar | Crossref | Medline4. Kalfus, IN, Graham, DY, Riff, DS, et al. Rifabutin-containing triple therapy (RHB-105) for eradication of Helicobacter pylori: randomized ERADICATE Hp trial. Antibiotics 2020; 9: 685.
Google Scholar | Crossref5. Graham, DY, Fischbach, L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59: 1143–1153.
Google Scholar | Crossref | Medline | ISI6. Graham, DY, Liou, JM. Primer for development of guidelines for Helicobacter pylori therapy using antibiotic stewardship. Clin Gastroenterol Hepatol 2021 (in press). DOI: 10.1016/j.cgh.2021.03.026.
Google Scholar7. Graham, DY . Transitioning of Helicobacter pylori therapy from trial and error to antimicrobial stewardship. Antibiotics 2020; 9: 671.
Google Scholar | Crossref8. Sugano, K, Tack, J, Kuipers, EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015; 64: 1353–1367.
Google Scholar | Crossref | Medline | ISI9. Graham, DY . Illusions regarding Helicobacter pylori clinical trials and treatment guidelines. Gut 2017; 66: 2043–2046.
Google Scholar | Crossref | Medline10. Graham, DY, Dore, MP. Helicobacter pylori therapy demystified. Helicobacter 2011; 16: 343–345.
Google Scholar | Crossref | Medline11. Rokkas, T, Gisbert, JP, Malfertheiner, P, et al. Comparative effectiveness of multiple different first-line treatment regimens for Helicobacter pylori infection: a network meta-analysis. Gastroenterology 2021; 161: 495–507.
Google Scholar | Crossref | Medline12. Graham, DY, Moss, SF. Antimicrobial susceptibility testing for Helicobacter pylori is now widely available: who, when, and how. Am J Gastroenterol 2021 (in press).
Google Scholar13. Glupczynski, Y, Labbe, M, Burette, A, et al. Treatment failure of ofloxacin in Campylobacter pylori infection [Letter]. Lancet 1987; 1: 1096–1096.
Google Scholar | Crossref | Medline14. Glupczynski, Y, Burette, A, De Koster, E, et al. Metronidazole resistance in Helicobacter pylori [Letter]. Lancet 1990; 335: 976–977.
Google Scholar | Crossref | Medline15. Bell, GD, Powell, K, Burridge, SM, et al. Experience with ‘triple’ anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pre- treatment bacterial isolate for metronidazole resistance. Aliment Pharmacol Ther 1992; 6: 427–435.
Google Scholar | Crossref | Medline16. Results of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori . European Study Group on Antibiotic Susceptibility of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1992; 11: 777–781.
Google Scholar | Medline17. Debets-Ossenkopp, YJ, Sparrius, M, Kusters, JG, et al. Mechanism of clarithromycin resistance in clinical isolates of Helicobacter pylori. FEMS Microbiol Lett 1996; 142: 37–42.
Google Scholar | Crossref | Medline18. Versalovic, J, Shortridge, D, Kibler, K, et al. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother 1996; 40: 477–480.
Google Scholar | Crossref | Medline19. Axon, AT . The role of omeprazole and antibiotic combinations in the eradication of Helicobacter pylori – an update. Scand J Gastroenterol Suppl 1994; 205: 31–37.
Google Scholar | Crossref | Medline20. Graham, DY, Opekun, AR, Klein, PD. Clarithromycin for the eradication of Helicobacter pylori. J Clin Gastroenterol 1993; 16: 292–294.
Google Scholar | Crossref | Medline | ISI21. Peterson, WL, Graham, DY, Marshall, B, et al. Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized, double-blind trial. Am J Gastroenterol 1993; 88: 1860–1864.
Google Scholar | Medline | ISI22. Graham, DY, Ramirez, F, Lew, GM, et al. Omeprazole as an adjuvant to antimicrobial therapy for eradication of Helicobacter pylori infection. Curr Therapeut Res 1994; 55: 213–219.
Google Scholar | Crossref23. FDA . BIAXIN Filmtabs (clarithromycin tablets). FDA full prescribing information, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050662s044s050,50698s026s030,050775s015s019lbl.pdf
Google Scholar24. Al-Assi, MT, Genta, RM, Karttunen, TJ, et al. Clarithromycin-amoxycillin therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1994; 8: 453–456.
Google Scholar | Crossref | Medline25. Lamouliatte, HC, Cayla, R, Megraud, F, et al. Amoxicillin-clarithromycin-omeprazole: the best therapy for Helicobacter pylori infection [Abstract]. Acta Gastroenterol Belg 1993; 56: A139.
Google Scholar26. Graham, DY . Hp-normogram (normo-graham) for assessing the outcome of H. pylori therapy: effect of resistance, duration, and CYP2C19 genotype. Helicobacter 2015; 21: 85–90.
Google Scholar | Crossref | Medline27. Graham, DY, Lu, H, Dore, MP. Relative potency of proton-pump inhibitors, Helicobacter pylori therapy cure rates, and meaning of double-dose PPI. Helicobacter 2019; 24: e12554.
Google Scholar | Crossref | Medline28. Graham, DY, Lu, H, Shiotani, A. Vonoprazan-containing Helicobacter pylori triple therapies contribution to global antimicrobial resistance. J Gastroenterol Hepatol 2021; 36: 1159–1163.
Google Scholar | Crossref | Medline29. Graham, DY . Vonoprazan Helicobacter pylori eradication therapy: ethical and interpretation issues. Gut 2017; 66: 384–386.
Google Scholar | Crossref | Medline30. Murakami, K, Sakurai, Y, Shiino, M, et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut 2016; 65: 1439–1446.
Google Scholar | Crossref | Medline | ISI31. Janssen, MJ, Van Oijen, AH, Verbeek, AL, et al. A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole. Aliment Pharmacol Ther 2001; 15: 613–624.
Google Scholar | Crossref | Medline32. Laheij, RJ, Rossum, LG, Jansen, JB, et al. Evaluation of treatment regimens to cure Helicobacter pylori infection—a meta-analysis. Aliment Pharmacol Ther 1999; 13: 857–864.
Google Scholar | Crossref | Medline33. Ginnebaugh, BD, Baker, J, Watts, L, et al. S1348 triple therapy for primary treatment of Helicobacter pylori: a 19-year U.S. Single Center Experience. J Am Coll Gastroenterol 2020; 115: S680–S681.
Google Scholar | Crossref34. Nyssen, OP, Bordin, D, Tepes, B, et al. European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. Gut 2021; 70: 40–54.
Google Scholar | Crossref | Medline35. Valle Muñoz, J, Muñoz Gómez, P, Sierra Bernal, C, et al. Tailored Helicobacter pylori eradication based on prior intake of macrolide antibiotics allows the use of triple therapy with optimal results in an area with high clarithromycin resistance. Rev Esp Enferm Dig 2019; 111: 655–661.
Google Scholar | Crossref | Medline36. Boltin, D, Levi, Z, Gingold-Belfer, R, et al. Impact of previous exposure to macrolide antibiotics on Helicobacter pylori infection treatment outcomes. Am J Gastroenterol 2019; 114: 900–906.
Google Scholar | Crossref | Medline37. Muñoz-Gómez, P, Jordán-Castro, JA, Abanades-Tercero, M, et al. Macrolide use in the previous years is associated with failure to eradicate Helicobacter pylori with clarithromycin-containing regimens. Helicobacter 2018; 23: e12452.
Google Scholar | Crossref38. Lim, SG, Park, RW, Shin, SJ, et al. The relationship between the failure to eradicate Helicobacter pylori and previous antibiotics use. Dig Liver Dis 2016; 48: 385–390.
Google Scholar | Crossref | Medline39. Shiota, S, Reddy, R, Alsarraj, A, et al. Antibiotic resistance of Helicobacter pylori among male United States veterans. Clin Gastroenterol Hepatol 2015; 13: 1616–1624.
Google Scholar | Crossref | Medline40. Megraud, F, Coenen, S, Versporten, A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62: 34–42.
Google Scholar | Crossref | Medline | ISI41. McNulty, CA, Lasseter, G, Shaw, I, et al. Is Helicobacter pylori antibiotic resistance surveillance needed and how can it be delivered? Aliment Pharmacol Ther 2012; 35: 1221–1230.
Google Scholar | Crossref | Medline42. McMahon, BJ, Hennessy, TW, Bensler, JM, et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med 2003; 139: 463–469.
Google Scholar | Crossref | Medline | ISI43. Perez Aldana, L, Kato, M, Nakagawa, S, et al. The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter 2002; 7: 306–309.
Google Scholar | Crossref | Medline44. Banatvala, N, Davies, GR, Abdi, Y, et al. High prevalence of Helicobacter pylori metronidazole resistance in migrants to east London: relation with previous nitroimidazole exposure and gastroduodenal disease. Gut 1994; 35: 1562–1566.
Google Scholar | Crossref | Medline45. El-Serag, HB, Kao, JY, Kanwal, F, et al. Houston consensus conference on testing for Helicobacter pylori infection in the United States. Clin Gastroenterol Hepatol 2018; 16: 992–1002.
Google Scholar | Crossref | Medline46. Liou, JM, Malfertheiner, P, Lee, YC, et al. Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut 2020; 69: 2093–2112.
Google Scholar | Crossref | Medline47. Shah, SC, Iyer, PG, Moss, SF. AGA clinical practice update on the management of refractory Helicobacter pylori infection: expert review. Gastroenterology 2021; 160: 1831–1841.
Google Scholar | Crossref | Medline48. Al-Eidan, FA, McElnay, JC, Scott, MG, et al. Management of Helicobacter pylori eradication – the influence of structured counselling and follow-up. Br J Clin Pharmacol 2002; 53: 163–171.
Google Scholar | Crossref | Medline49. Graham, DY, Mohammadi, M. Synopsis of antibiotic treatment. In: Kim, N (ed.) Helicobacter pylori. Singapore: Springer Science + Business Media, 2016, pp. 417–426.
Google Scholar | Crossref50. Adherence to long-term therapies. Evidence for action . Geneva: World Health Organization, 2003.
Google Scholar51. Blaschke, TF, Osterberg, L, Vrijens, B, et al. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol 2012; 52: 275–301.